Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer
作者:Shengtao Xu、Hong Yao、Yangyi Qiu、Manzhen Zhou、Dahong Li、Liang Wu、Dong-Hua Yang、Zhe-Sheng Chen、Jinyi Xu
DOI:10.1021/acs.jmedchem.1c01411
日期:2021.12.9
scaffold-hopping approach to identify a series of novel polycyclic heterocyclic derivatives based on Evo as the topoisomerase I (Top1) inhibitor for the treatment of triple-negative breast cancer (TNBC), which is an aggressive subtype of breast cancer with limited treatment options. The most potent compound 7f inhibited cell growth in a human breast carcinoma cell line (MDA-MB-231) with an IC50 value of 0.36 μM. Further
Evodiamine (Evo) 是一种在吴茱萸中发现的喹唑啉咔啉生物碱,具有中等的抗增殖活性。在此,我们报告了使用支架跳跃方法来鉴定一系列基于 Evo 的新型多环杂环衍生物作为拓扑异构酶 I (Top1) 抑制剂,用于治疗三阴性乳腺癌 (TNBC),这是一种侵袭性乳腺癌亚型治疗选择有限的癌症。最有效的化合物7f抑制人乳腺癌细胞系 (MDA-MB-231) 中的细胞生长,IC 50值为 0.36 μM。进一步的研究表明,Top1 是7f的目标,直接诱导不可逆的Top1-DNA共价复合物形成或通过活性氧介导的间接机制诱导氧化性DNA损伤。更重要的是,体内研究表明,7f在 TNBC 患者来源的肿瘤异种移植模型中表现出有效的抗肿瘤活性。这些结果表明,化合物7f作为治疗 TNBC 的有希望的候选者值得进一步研究。